Current Report Filing (8-k)
December 14 2021 - 4:06PM
Edgar (US Regulatory)
0001279704
false
0001279704
2021-12-08
2021-12-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 8, 2021
CELLECTAR
BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
1-36598
|
|
04-3321804
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
100
Campus Drive, Florham Park, New Jersey 07932
(Address of principal executive offices, and zip code)
(608)
441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common stock, par value $0.00001
|
|
CLRB
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
On December 8, 2021,
Cellectar Biosciences, Inc. (the “Company”) issued a press announcing its poster presentation at the 63rd American Society
for Hematology Annual Meeting and Exposition (the “ASH Meeting”). A copy of the press release is furnished as Exhibit 99.1
and is incorporated by reference herein.
On December 13, 2021,
the Company issued a press release announcing that the Company has presented data from its ongoing Phase 2 CLOVER-1 Study of Iopofosine
I-131 at the ASH Meeting. A copy of the press release is furnished as Exhibit 99.2 and is incorporated by reference herein.
The information in this
Item 7.01 and Exhibits 99.1 and 99.2 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall
not be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: December 14, 2021
|
CELLECTAR BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Dov Elefant
|
|
|
Name:
|
Dov Elefant
|
|
|
Title:
|
Chief Financial Officer
|
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2023 to Jul 2024